INCY - Incyte posts late-stage ruxolitinib COVID-19 study results

Incyte (INCY) announces results from the Phase 3 DEVENT study evaluating the efficacy and safety of ruxolitinib (5mg and 15mg) plus standard of care ((SoC)) versus SoC in patients on mechanical ventilation with COVID-19 associated Acute Respiratory Distress Syndrome ((ARDS)).The study did not meet its primary endpoint of mortality due to any cause through day 29.In the U.S. study population (N=191), which accounts for the majority (91%) of the DEVENT study patients, there was a clinically and statistically significant improvement in mortality in each of the 5mg and 15mg treatment arms versus placebo, respectively.Incyte said that it plans to make ruxolitinib available to eligible patients in the US at no cost via an Expanded Access Program ((EAP)) pending agreement with the U.S. FDA.

For further details see:

Incyte posts late-stage ruxolitinib COVID-19 study results